The American Academy of Dermatology (AAD) held its annual meeting in Miami, Florida during the first weekend in March, bringing together hundreds of physicians from around the country to discuss the latest innovations in laser skin resurfacing devices and techniques, and the latest advances in treating aging skin.
Several vendors and exhibitors unveiled new devices over the course of the event.
Johnson & Johnson demonstrated its CYTOMIMIC Technology that combines essential minerals to deliver biological levels of electric signals deep into the skin to match the skin’s bioelectricity. The technology is designed to rejuvenate, repair and renew the skin from inside out, and clinical studies showed a significant improvement in the skin’s appearance starting within minutes of the application. The technology promotes an increase in cellular activity by triggering the production of collagen and elastin, while reducing the signs of aging.
Another highlight of the meeting was the unveiling of data evaluating the safety and effectiveness of psoriasis treatments STELARA and REMICADE. Both of these products had been tested for approximately 18 months and results of the study showed that STELAR, a prescription medicine that affects the immune system, and REMICADE, the first anti-TNF-alpha treatment to be approved in gastroenterology, dermatology and rheumatology, offer some attractive options for managing the chronic disease.
Fractional resurfacing devices were also a hot topic at this year’s meeting, and Syneron unveiled its e2 sublative laser system that works at the epidermal and dermal levels to reduce the signs of aging and improve the skin’s appearance. The e2 device is an innovative non-invasive laser resurfacing procedure that helps remove moderate lines and wrinkles, and also increase collagen production so the skin appears more resilient and toned.
Demand for fractional resurfacing treatments with little downtime is still strong, as more patients search for non-surgical options for removing lines and wrinkles.